Post-earnings recap
Reported
Wed, Oct 24, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a slight miss on EPS, which contributed to a 0.97% decline in stock price. The lack of revenue data and guidance may have raised concerns among investors. Management's cautious tone reflects ongoing challenges but a commitment to future growth through innovation.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | -1.07% |
Management expressed a cautious optimism regarding future growth despite current market challenges. They emphasized their commitment to innovation and strategic investments.
Management highlighted ongoing investments in innovation.
They noted challenges in certain markets but remain focused on long-term growth.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—